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ABSTRACT: L-Type amino acid transporter 1 (LAT1),
selectively expressed at the blood−brain barrier (BBB) and
brain parenchymal cells, mediates brain delivery of drugs and
prodrugs such as L-dopa and gabapentin. Although knowledge
about BBB transport of LAT1-utilizing prodrugs is available,
there is a lack of quantitative information about brain
intracellular delivery and influence of prodrugs on the
transporter’s physiological state. We studied the LAT1-
mediated intrabrain distribution of a recently developed prodrug of the cyclooxygenase inhibitor ketoprofen as well as its
impact on transporter protein expression and function (i.e., amino acid exchange) using brain slice method in mice and rats.
The intrabrain distribution of the prodrug was 16 times higher than that of ketoprofen. LAT1 involvement in brain cellular
barrier uptake of the prodrug was confirmed, reflected by a higher unbound brain intracellular compared to brain extracellular
fluid concentration. The prodrug did not alter LAT1 protein expression and amino acid exchange. Integration of derived
parameters with previously performed in vivo pharmacokinetic study using the Combinatory Mapping Approach allowed to
estimate the brain extra- and intracellular levels of unbound ketoprofen, prodrug, and released parent drug. The overall
efficiency of plasma to brain intracellular delivery of prodrug-released ketoprofen was 11 times higher than after ketoprofen
dosing. In summary, this study provides quantitative information supporting the use of the LAT1-mediated prodrug approach
for enhanced brain delivery of drugs with intracellular targets.
KEYWORDS: pharmacokinetics, transporter, LAT1, prodrug, intrabrain distribution, brain slice
■ INTRODUCTION
Drug delivery to the brain is an enormous challenge for the
treatment of central nervous system (CNS) diseases, in
particular neurodegenerative disorders. Various brain delivery
approaches have been devised to overcome this problem.1,2
Feasible brain delivery methods should be based on an
understanding of the target nature and localization within the
brain. Although a tremendous number of current drug targets
are present in the brain extracellular space, many targets are
localized in the brain parenchymal cells.3−5 In order to interact
with an intracellular target within the brain, an unbound drug
needs to cross both the blood−brain barrier (BBB) and the
membrane barrier of brain parenchymal cells and reach the
intracellular compartment at a therapeutically effective
concentration. One promising approach to deliver CNS
drugs is to develop prodrugs resembling endogenous substrates
of influx transporters, which are selectively expressed at the
BBB and the membrane of the brain parenchymal cells. Thus,
after transporter-mediated delivery of the prodrug across the
BBB and cellular membrane barrier, the parent drug will be
released at its target siteinside the brain parenchymal cells.
In this respect, the L-type amino acid transporter 1 (LAT1)
has been successfully exploited for the brain delivery of the
dopamine prodrug, L-dopa, as well as for gabapentin.6 This
transporter (Figure 1) is a pH- and Na+-independent
heterodimeric antiporter composed of light chain subunit
LAT1 (SLC7A5) and heavy chain subunit CD98 (SLC3A2,
also known as 4F2hc).7 The LAT1 is responsible for the
exchange of large branched and aromatic neutral amino acids
(phenylalanine, leucine, histidine, tyrosine, etc.), and it plays a
crucial role in the normal development and function of the
CNS. The CD98 is a glycoprotein coupled with a light chain
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that functions as a molecular chaperone localizing LAT1 in
plasma membrane as well as playing a role in cell survival.8 The
expression of the LAT1 (subsequently referred to as LAT1/
CD98) on both luminal and abluminal membranes of brain
capillary endothelial cells as well as at the brain parenchymal
cells could be exploited for brain intracellular delivery.9−14
Recently, we analyzed the structure−pharmacokinetic (PK)
relationship of five LAT1-utilizing prodrugs of the cyclo-
oxygenase (COX) inhibitor, ketoprofen.15 The COX inhibitors
have been reported to diminish the risk of development of
Alzheimer’s disease (AD),16,17 as the COX enzyme has been
postulated to be involved in AD pathogenesis.18,19 However,
since COX is abundantly expressed in peripheral organs, this
means that conventional administration of COX inhibitors
such as ketoprofen can be associated with systemic side
effects.20 The structure−PK relationship analysis revealed that
two prodrugs with phenylalanine promoiety conjugated in
meta- and para-positions to ketoprofen could cross the BBB
and deliver the parent drug into the brain after i.p. injection of
a single dose in wild-type mice.15 Moreover, the distribution
between liver and brain for released ketoprofen from these
prodrugs was five times lower compared to that after
ketoprofen dosing.15
However, as the COX is expressed intracellularly, it is crucial
to elucidate whether and to what extent the prodrugs can cross
the brain−cellular barrier and then subsequently release
ketoprofen inside the brain parenchymal cells. Currently,
there is only limited quantitative information about intrabrain
distribution of LAT1-utilizing prodrugs. Gynther et al.
provided the first evidence for intracellular brain delivery of
a lysine-prodrug of ketoprofen in rats.22 In that study, the
prodrug rapidly reached the brain parenchymal cells from the
brain extracellular fluid (ECF), while ketoprofen distributed
mainly into the ECF. These results highlighted the potential of
exploiting an LAT1-utilizing prodrug approach for brain
intracellular delivery of drugs.
The assessment of brain delivery of drugs with intracellular
targets via LAT1-utilizing prodrugs is a complex process since
it involves monitoring the concentrations of both unbound
prodrug and released parent drug in various brain compart-
ments. Moreover, the bioconversion of the prodrug can occur
in plasma and peripheral tissues; therefore, it is essential to
elucidate if the release occurs in the brain. The gold standard
method for “dissecting” these processes is in vivo cerebral
microdialysis since this provides information about brain
extracellular concentrations of unbound drugs over time. The
development of a high-throughput in vitro brain slice
technique has led to the introduction of the combinatory
mapping approach (CMA)an alternative method to cerebral
microdialysis.23−26 CMA integrates the data from in vitro brain
slice and homogenate experiments as well as PK studies,
providing a time-efficient and reliable estimation of the BBB
and brain−cellular barrier transport extent of unbound
drug.23,26,27 The latter is performed by evaluating the key
neuropharmacokinetic (neuroPK) parameters: unbound brain
to plasma concentration ratio (Kp,uu,brain) and unbound intra- to
extracellular concentration ratio (Kp,uu,cell).
The aim of the present study was to provide mechanistic
insights into the intrabrain distribution of prodrugs utilizing
influx transporters exemplified by LAT1 for brain delivery of
drugs with intracellular targets in mice and rats. For this
purpose, we used the LAT1-utilizing prodrug of ketoprofen
(denoted as prodrug 1), which previously proved capable of
delivering ketoprofen into the mouse brain.15 This is the first
time that the involvement of LAT1 in intrabrain distribution of
LAT1-utilizing prodrug has been investigated using the brain
slice method. The effect of the prodrug on LAT1 protein
expression and function was evaluated. Furthermore, we
propose and discuss additional steps to the previously devised
screening strategy15 for application in the development of
prodrugs utilizing influx transporters.
■ EXPERIMENTAL SECTION
Chemicals. Ketoprofen was obtained from Sigma-Aldrich
(St. Louis, MO, USA). Prodrug of ketoprofen (prodrug 1;
(2R,S)-2-amino-3-(3-(2-(3-benzoylphenyl)propanamido)-
phenyl)propanoic acid) and LAT1 inhibitor (KMH-233; (S)-
2-amino-3-(3-((2,4-dicyano-3-(4-(2-(methylamino)-2-
oxoethoxy)phenyl)benzo[4,5]imidazo[1,2-a]pyridin-1-yl)-
carbamoyl)phenyl)propanoic acid) were synthesized based on
a previously published protocol (Figure S1).15,28 Isoflurane was
purchased from Baxter Medical AB (Kista, Sweden), while 100
IU/mL heparin was from Leo Pharma AB (Malmö, Sweden).
Diclofenac, which was used as the internal standard for the
liquid chromatography−tandem mass spectrometry (LC−MS/
MS) analysis of ketoprofen, was purchased from Sigma-Aldrich
(St. Louis, MO). Internal standard peptides for quantitative
proteomics analysis were purchased from JPT Peptide
Technologies GmbH (Berlin, Germany). Lysyl endopeptidase
(Lys-C), Protease-Max surfactant, and tosylphenylalanyl
chloromethyl ketone-treated trypsin were from Promega
(Madison, WI, USA). Other solvents and reagents used for
intrabrain distribution study and LC−MS/MS were of high
purity analytical grade or HPLC grade and were purchased
from J.T. Baker (Deventer, The Netherlands), Riedel-de Haen̈
(Seelze, Germany), Sigma (St. Louis, MO, USA), or Merck
(Darmstadt, Germany). Saline solution was obtained from
Braun Medical AB (Stockholm, Sweden). The water was
purified using a Milli-Q Gradient system (Millipore, Bedford,
Massachusetts and Millipore, Milford, USA).
Selection of the Prodrug. A meta-substituted phenyl-
alanine derivative of ketoprofen (Figure S1) was selected from
the previous study (denoted as prodrug 1) based on the
following characteristics.15 The prodrug utilized LAT1 for the
cellular uptake in vitro in human retinal pigmented epithelial
cells (ARPE-19) crossed the BBB after in situ brain perfusion
Figure 1. Representation of the transport of essential (phenylalanine,
Phe; leucine, Leu; histidine, His; tyrosine, Tyr) and nonessential
(glutamine, Gln) amino acids via heterodimeric transporter LAT1/
CD98 across the cell membrane. LAT1 has higher affinities for L-
amino acids compared to D-form as shown for Phe and Leu.21
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in adult C57BL/6 male mice. Moreover, after an i.p. injection
of a single dose (25 μmol/kg) in C57BL/6 male mice (30 ± 5
g, n = 3 per compound/time point), the prodrug released
ketoprofen in the brain. The ratio of areas under the
concentration−time curve from time zero to 360 min for
unbound ketoprofen in brain and plasma (AUCu,brain/
AUCu,plasma) estimated using the unbound fraction in brain
and plasma determined with equilibrium dialysis was 13 times
higher after prodrug dosing compared to ketoprofen
administration. In addition, the distribution between liver
and brain of ketoprofen (AUCu,liver/AUCu,brain) was 5 times
lower after prodrug dosing than that after ketoprofen
administration.
Animals. The intrabrain distribution study using the brain
slice technique was conducted in drug-naiv̈e male Sprague−
Dawley rats (250−300 g) and male C57BL/6 (20−25 g) mice
in the Department of Pharmaceutical Biosciences, Uppsala
University. The study protocol was approved by the Animal
Ethics Committee (C189/14). The animals were obtained
from Taconic (Lille Skensved, Denmark). The animals (21
rats; 21 mice) were group-housed in stainless steel cages at an
ambient temperature of 20−22 °C with a humidity-controlled
environment under a 12 h light/dark cycle. The animals had ad
libitum access to food and tap water.
Intrabrain Distribution Study Using an in Vitro Brain
Slice Method. Assessment of the Unbound Volume of
Distribution in the Brain. The study of intrabrain distribution
of ketoprofen and its prodrug in the brain of mice (n = 3 per
study group) or rats (n = 3 per study group) was performed
with the previously published brain slice protocol with small
modifications.23,25 Briefly, six and ten 300 μm coronal slices
were prepared from each rat or mouse brain, respectively, using
a vibrating blade microtome Leica VT1200 (Leica Micro-
systems AB, Sweden). The slices were placed in an 80 mm
diameter beaker, containing 15 mL (for rats) or 12 mL (for
mice) of preoxygenated artificial extracellular fluid (aECF)
with either 0.2 μM ketoprofen or 0.2 μM prodrug. The aECF
used to maintain the brain slices contained 129 mM NaCl, 3
mM KCl, 1.2 mM MgSO4, 0.4 mM K2HPO4, 1.4 mM CaCl2,
10 mM glucose, and 25 mM HEPES, and 0.4 mM ascorbic
acid. At room temperature, the aECF pH was adjusted to 7.6.
The beakers, covered by a lid made of a Teflon fluorinated
ethylene-propylene film (Teflon FEP film 50 Å, 12.7 μm
thickness), were incubated in a shaker (MaxQ4450, Thermo
Fisher Scientific, NinoLab, Sweden) at 37 °C, 45 rpm, for 5 h
under a constant flow of oxygen in the incubation chamber to
preserve slice viability. When studying the dynamics of uptake
of the compounds, 200 μL of aECF buffer was collected at the
beginning of the experiment, and at 0.5, 1, 1.5, 2, 3, 4, and 5 h
after incubation in Eppendorf tubes, containing 200 μL of
blank rat or mouse brain homogenate in aECF (1:4, w/v)
without the investigated compounds. The latter was performed
to ensure matching of the matrix composition among all
samples in the subsequent analysis. After 5 h incubation, the
excess buffer was carefully removed from the brain slices with a
filter paper. The slices were weighed and homogenized in
aECF (1:9, w/v) individually with an ultrasonic processor
(VCX-130, Sonics, Chemical Instruments AB, Sweden). All
samples were stored at −20 °C until LC−MS/MS analysis as
described below. The viability of the brain slices was studied
via a dynamic pH measurement and assessment of lactate
dehydrogenase activity release using a cytotoxicity detection kit
(Roche Diagnostics GmbH, Germany).
In the assessment of intrabrain distribution, we determined
Vu,brain(mL/g brain), a neuroPK parameter describing drug
intrabrain distribution driven by various processes including
nonspecific and specific brain tissue binding, active transport
across cellular membrane, and pH partitioning of the drug. The
evaluation assumes that at equilibrium the concentration of the
compounds in the virtually protein-free aECF in the beaker is
equal to the brain interstitial fluid or ECF unbound
concentration in the brain slice. In context of physiological
volumes of brain fluids, Vu,brain > 0.8 mL/g brain represents the
intracellular distribution and/or tissue binding, and/or
distribution to subcellular organelles, while Vu,brain < 0.8 mL/
g brain represents the distribution to the brain ECF with
minimal protein or membrane binding.25 Vu,brain was calculated












where Abrain (nmol/g brain) is the drug amount in the brain
slice, Cbuffer is the aECF concentration of compounds after 5 h
incubation; Vi (mL/g brain), the volume of the surrounding
brain slices layer of aECF, equal to 0.094 mL/g brain, was used
based on previous studies with marker [14C]-inulin.23
As a direct measurement of intracellular unbound concen-
trations is currently not feasible, the intracellular-to-extrac-
ellular partitioning coefficient (Kp,uu,cell) for unbound ketopro-
fen and prodrug was estimated using eq 2 introduced by
Friden et al.27 Herein, the eq 2 is used for Kp,uu,cell calculation,
while theoretical and mathematical details can be found in
Friden et al.27 Kp,uu,cell describes the distribution of the
unbound compound between the brain intracellular fluid
(ICF) and extracellular compartment, representing an average
ratio for all types of parenchymal cells at steady-state. The
estimation of the parameter assumes that the compounds are
unbound in brain ECF. Kp,uu,cell ≥ 1 represents the intracellular
distribution of the compounds, while Kp,uu,cell < 1 reflects the








where Vu,brain is the unbound volume of distribution; Vbrain,ECF
is the physiological fractional volume of the brain ECF,
estimated to be 0.2 mL/g brain;29 VICF is the physiological
fractional volume of the intracellular compartment, estimated
to be 0.8 mL/g brain;30 Vu,ICF is the distribution volume of
unbound drug in the ICF. It characterizes the drug intracellular














where f u,homogenate is an unbound fraction of the investigated
compound in diluted brain homogenate determined by
equilibrium dialysis described in section Equilibrium Dialysis.
Evaluation of LAT1 Contribution to Intrabrain Distribu-
tion of Prodrug. The intrabrain distribution of the prodrug in
mice and rats (n = 3 per species) was studied in the presence
of the recently developed selective LAT1 inhibitor (KMH-
233).28 The brain slices were preincubated in aECF containing
800 nM LAT1-inhibitor for 30 min before adding 200 nM
prodrug into the beaker. Subsequently, aECF samples were
collected at 0.5, 1, 1.5, 2, 3, 4, and 4.5 h after adding the
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prodrug. The brain slices were collected at 4.5 h after adding
the prodrug and stored at −20 °C prior to the LC−MS/MS
analysis, as the optimal time for the slice study is 5 h.
Consequently, Vu,brain and Kp,uu,cell for the prodrug were
calculated according to eqs 1 and 2. We assumed that the
LAT1 inhibitor would have no impact on the brain tissue
binding properties of the prodrug. Therefore, in the
calculations, the same f u,homogenate of the prodrug was used, as
that measured without LAT1 inhibitor.
Profiling of Transporter Protein Expression and Amino
Acids Levels in Brain Slice Study. In the quantitative protein
expression and amino acid analysis, the brain slices from rats (n
= 3 per experiment) and mice (n = 3 per experiment), which
had been incubated for 5 h in aECF with or without 200 nM
prodrug or 800 nM LAT1 inhibitor were collected, weighed,
and stored in Eppendorf tubes at −80 °C until LC−MS/MS
analysis. The nonincubated control brain slices from mice (n =
3) and rats (n = 3) were collected and stored in Eppendorf
tubes at −80 °C until LC−MS/MS analysis. During the
experiment, 500 μL (rat slices) and 250 μL (mouse slices) of
aECF buffer were collected before incubation, after 1 and 5 h
of incubation into Eppendorf tubes for amino acid analysis.
Samples were stored at −80 °C until LC−MS/MS analysis
(section Bioanalysis of Samples).
Equilibrium Dialysis. The homogenate method was used
to determine the unbound fraction of the prodrug and LAT1
inhibitor in rat brain homogenate in phosphate-buffered saline
(PBS), pH 7.4 (1:4, w/v) using an equilibrium dialysis
technique. Briefly, the investigated compounds were added to
the brain homogenate at a final concentration of 10 μM,
vortexed, and placed (100 μL) in the sample chamber of the
rapid equilibrium dialysis (RED) devices (Thermo Scientific,
Woburn, MA). PBS (350 μL) was added to the corresponding
buffer chamber. The homogenate was dialyzed in a shaker at
200 rpm and 37 °C for 5 h. Samples from both chambers were
taken, and an equal volume of blank homogenate or PBS was
added to ensure analytical identity. The unbound fraction
( f u,brain) of prodrug and LAT1 inhibitor in the brain was





D D f( 1)u,brain
u,homogenate
u,homogenate (4)
where D is the dilution factor of tissue (D = 5) and f u,homogenate
is the ratio of compound concentration measured in the tissue
sample and buffer within the equilibrium dialysis assay. The
unbound fraction of ketoprofen, the prodrug, and LAT1
inhibitor in plasma ( f u,plasma) and mouse brain as well as the
unbound fraction of ketoprofen in rat brain were determined
using a similar method and have been reported previ-
ously.15,22,28
It is considered that fu,brain measured by the brain
homogenate method is equal to 1/Vu,brain, if the drug
distribution within the cell is mainly driven by nonspecific
and specific binding, and not by active uptake or efflux.32
However, when active processes are involved, f u,brain may
under- or overestimate the value of Vu,brain, which may
contribute to errors in the subsequent assessment of Kp,uu,brain.
Evaluation of NeuroPK Parameters. The CMA was used
to determine the parameters describing the BBB transport and
intrabrain distribution of ketoprofen and the prodrug in
mice.15,26 In addition, we estimated the contribution of
ketoprofen released in plasma to the brain intracellular levels
of unbound released ketoprofen after dosing of the prodrug. In
our previous PK study after an i.p. injection of a single dose
(25 μmol/kg) of either ketoprofen or prodrug in mice,
AUCu,brain and AUCu,plasma were estimated using the unbound
fraction in brain and plasma determined with equilibrium
dialysis.15 However, AUCu,brain determined with brain homo-
genate does not provide a comprehensive picture of the
intrabrain distribution of the prodrug and release of
ketoprofen. In the current study, the extent of the brain
delivery and intrabrain distribution of ketoprofen and prodrug
in mice was estimated with the more reliable brain slice
method via the evaluation of Vu,brain combined with the
previously reported PK parameters.15
Extent of Brain Delivery of Ketoprofen and Prodrug. The
extent of delivery of investigated compounds across the BBB
was evaluated by calculating the ratio of total concentrations in
brain and plasma (Kp,brain, eq 5), and the unbound brain ECF











where AUCtotal,brain and AUCtotal,plasma are areas under the total
concentration−time curve from time zero to 360 min in brain
and plasma, respectively, measured after the 25 μmol/kg single
dose of either ketoprofen or prodrug i.p. in mice.15 The brain
total concentration was corrected for the residual blood
concentration using the method described by Murakami et
al.33 The f u,plasma is the unbound fraction of compound in
plasma.
Kp,uu,brain has the advantage that it provides quantitative
information about the net flux of drug across the BBB,
including active and passive transport without the impact of
plasma and brain tissue binding. A value of Kp,uu,brain < 1
indicates that there is active efflux of the drug from the brain,
while Kp,uu,brain > 1 is evidence of an active influx of the drug
into the brain.
Estimation of Intracellular and Extracellular Distribution
of Ketoprofen and Prodrug. After crossing the BBB, the
unbound compound enters the brain ECF, and this is followed
by its distribution to the brain parenchymal cells. The
AUCu,brainECF for unbound ketoprofen and prodrug was








The AUCu,brainICF for unbound ketoprofen and prodrug was








ICF u,ICF u,brain (8)
Estimation of Intracellular and Extracellular Distribution
of Ketoprofen Released in Plasma. The AUCtotal,brain of
ketoprofen includes both ketoprofen released in the brain and
ketoprofen that has entered from plasma. Therefore, eqs 9 and
10 were used for the estimation of AUCu,brainECF and
AUCu,brainICF of unbound ketoprofen, respectively, which was
released in plasma from the prodrug and further distributed
into the brain ECF after crossing the BBB:
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= K fAUC AUC ,u,brainECF p,uu,brain total plasma u,plasma (9)
= KAUC AUCu,brainICF p,uu,cell u,brainECF (10)
where AUCtotal,plasma of released ketoprofen had been quantified
in the previous PK study after prodrug dosing.15 We assumed
that ketoprofen released in plasma from the prodrug would
follow similar kinetics as after ketoprofen dosing. Therefore,
the same values for Kp,uu,brain and Kp,uu,cell as those calculated for
ketoprofen administration were used.
Estimation of Intracellular Release of Ketoprofen. The
main assumption of the prodrug approach is that bioconver-
sion to the parent drug occurs in the intracellular compartment
including brain parenchymal cells. AUCtotal,brain of ketoprofen
quantified after prodrug dosing does not allow for the
estimation of the site of bioconversion. Therefore, a general
approach described by eqs 7 and 8 was used to estimate
AUCu,brainECF and AUCu,brainICF, respectively, for ketoprofen
released from the prodrug in the brain ECF and ICF. The
estimated AUCu,brainECF and AUCu,brainICF included both
ketoprofen released in the brain and delivered from plasma
after prodrug dosing. Therefore, AUCu,brainICF of ketoprofen
distributed to the ICF from plasma (section Estimation of
Intracellular and Extracellular Distribution of Ketoprofen
Released in Plasma) was subtracted from AUCu,brainICF
including the ketoprofen released in plasma and brain to
estimate AUCu,brainICF of unbound ketoprofen released in the
intracellular compartment of the brain. Thus, the estimated
AUCu,brainICF of ketoprofen released in the brain intracellular














u,brainICF(plasma released ketoprofen) (11)
AUCtotal,brain of ketoprofen released in the whole brain after
prodrug dosing had been quantified previously,15 AU-
Cu,brain (plasma‑released ketoprofen) is unbound ketoprofen, which has
been released in plasma from the prodrug and further
distributed into the brain ECF after crossing the BBB followed
by entering the brain ICF (calculated in section Estimation of
Intracellular and Extracellular Distribution of Ketoprofen
Released in Plasma).
This approach is based on the fact that unbound ketoprofen
achieves an equilibrium between brain ECF and ICF. It is
important to remember that if the bioconversion occurs inside
the parenchymal cells, then the process will be more complex,
and equilibrium is only reached when the rate of elimination
from the brain ICF, or binding or distribution to cell organelles
of released unbound ketoprofen, is equal to the bioconversion
rate inside the cells. However, as this cannot be proved, this
approach may underestimate AUCu,brainICF values and over-
estimate AUCu,brainECF values.
Bioanalysis of Samples. Quantification of Ketoprofen,
Prodrug, and LAT1 Inhibitor. In the quantification of
ketoprofen, prodrug, and the LAT1 inhibitor in experimental
samples, an aliquot of 100 μL of the homogenates from brain
slices or equilibrium dialysis samples was precipitated by
adding 300 μL of acetonitrile containing the internal standard,
diclofenac (50 nM). The samples were vortexed and
centrifuged for 10 min at 14000 × g at 4 °C. Consequently,
100 μL of supernatant was mixed with 100 μL of water before
the LC−MS/MS analysis described below. The calibration
curve standards and blank samples were prepared in a similar
way in the respective control matrices. The accuracy, precision,
linearity, and lower limits of quantification (LLOQ) for the
LC−MS/MS methods were tested according to the European
Medicines Agency (EMA) guideline.34 The calibration curves
were considered acceptable, when accuracy and precision were
>20% for the LLOQ and >15% for the whole measurement
range.
The LC−MS/MS quantification of ketoprofen, prodrug, and
LAT1 inhibitor was performed using the previously described
methods.15,28 Briefly, the compounds were separated in an
Agilent 1200 Series Rapid Resolution LC System (Agilent
Technologies, Waldbronn, Germany) coupled with Agilent
6410 Triple Quadrupole Mass Spectrometer with an electro-
spray ionization (ESI) source (Agilent Technologies, Palo
Alto, CA, USA). Poroshell 120 EC-C-18 column (50 mm ×
2.1 mm, 2.7 μm) was used. The aqueous eluent phase
contained 0.1% formic acid in water, while the organic phase
consisted of pure acetonitrile. The gradient for mobile phase in
the analysis of ketoprofen and prodrug was as follows: (0−0.5
min) 20% organic phase, (0.5−1 min) 20−80% organic phase,
(1−4.5 min) 80% organic phase followed by 3.5 min
equilibration of the column with a flow rate of 0.4 mL/min.
A gradient elution for the LAT1 inhibitor was as follows: (0−1
min) 20% organic phase, (1−3 min) 20−90% organic phase
followed by a 3 min column equilibration with a flow rate of
0.3 mL/min. Mass spectrometric detection was performed with
multiple reaction monitoring (MRM) in the positive mode
with the following transitions: 255 → 209 for ketoprofen; 417
→ 134.8 for the prodrug; 588 → 191.6 for the LAT1 inhibitor;
and 296.1 → 250 for diclofenac. Data was acquired using the
software Agilent MassHunter Workstation Acquisition (Agilent
Technologies, Data Acquisition for Triple Quad., B.03.01) and
processed with Quantitative Analysis (B.04.00) software. All
samples were within the identified linear range of individual
calibration curves (determination coefficients R2 > 0.980). The
LLOQ of ketoprofen, LAT1 inhibitor, and prodrug were 5, 10,
and 1 nM, respectively.
Protein Quantification Analysis. The protein expression
levels of LAT1, CD98, glucose transporter type 1 (GLUT1),
and Na+/K+-ATPase in crude membrane fractions of mouse
and rat brain slices were quantified using multiplexed MRM
analysis according to the protocol described by Uchida et al.35
GLUT1 was used as a marker, indicating changes in cellular
energy metabolism during the experiments. First, the crude
membrane fractions were isolated using ProteoExtract
Subcellular Proteome Extraction Kit (Merck KGaA, Darm-
stadt, Germany) according to the manufacturer’s instructions.
The aliquots (50 μg of protein) were solubilized in 7 M
guanidine hydrochloride, 500 mM Tris−HCl (pH 8.5), and 10
mM EDTA. The proteins were reduced with dithiothreitol and
S-carbamoylmethylated with iodoacetamide. Subsequently,
proteins were precipitated with methanol and chloroform.
The precipitates were dissolved by addition of 6 M urea in 0.1
M Tris−HCl (pH 8.5) followed by a 5-fold dilution with 0.1 M
Tris−HCl (pH 8.5), which was spiked with a mixture of
internal standard peptides. This step was followed by the
addition of Lys-C and Protease-Max and incubation at room
temperature for 3 h. Finally, tosylphenylalanyl chloromethyl
ketone-treated trypsin was added for tryptic digestion of the
samples (enzyme/substrate ratio of 1:100), which were
incubated at 37 °C for 16 h. Formic acid in water 20% (v/
v) was used to acidify the samples, followed by centrifugation
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at 14000 × g for 5 min at 4 °C. The supernatants were
subjected to LC−MS/MS analysis.
The LC−MS/MS analysis was conducted by coupling using
an Agilent 1290 Infinity LC (Agilent Technologies, Wald-
bronn, Germany) system to an Agilent 6495 Triple Quadru-
pole Mass Spectrometer equipped with an ESI source (Agilent
Technologies, Palo Alto, CA, USA). The HPLC method used
for separation and elution of peptides has been described
previously using AdvanceBio Peptide Map column (2.1 × 250
mm, 2.7 μm).36 The eluted peptides were simultaneously
detected using the positive ion MRM mode. The dwell time
was 20 ms per transition. The source temperature was 210 °C
with drying gas at a flow rate of 16 L/min. The nebulizer
pressure was 45 psi and MS capillary voltage was 3 kV. The
quantitation of the target protein was based on one unique
peptide selected according to the in silico peptide selection
criteria and previous reports.35,37 Three or four MRM
transitions for each specific peptide related to high intensity
fragment ions were selected for quantification of a stable
isotope-labeled peptide and the unlabeled investigated peptide
(Table S1). Data were acquired using the Agilent MassHunter
Workstation Acquisition software (Agilent Technologies, Data
Acquisition for Triple Quad., version B.03.01) and processed
with Skyline software (version 4.1). The expression levels of
target proteins in crude membranes of mouse and rat brain
slices were expressed as absolute values and as a ratio
normalized to the expression level of Na+/K+-ATPase, a
membrane marker, to allow comparison of protein expression
between samples.38
Analysis of Amino Acids in Brain Slices and aECF. In the
quantification of amino acids in the experimental samples,
brain slices (10−20 mg) were homogenized (1:20, w/v) in
80% methanol in water. The samples were vortexed and
centrifuged for 10 min at 14000 × g at 4 °C. Then, 200 μL of
supernatant was used for the analysis described below. The
quantifications of L-phenylalanine (L-Phe) and L-glutamine (L-
Gln) (analysis 1) in brain slices and aECF were carried out
using the previously reported method with the UHPLC-
QTOF-MS System (Agilent Technologies 1290 LC, 6540 MS,
Agilent Technologies, Santa Clara, CA, USA).39 In the
quantification of L-tyrosine (L-Tyr), L-histidine (L-His), and
L-leucine (L-Leu) (analysis 2), an Agilent 1200 Series Rapid
Resolution LC System (Agilent Technologies, Waldbronn,
Germany) was used coupled with Agilent 6410 Triple
Quadrupole Mass Spectrometer with an electrospray ionization
source (Agilent Technologies, Palo Alto, CA, USA). Hydro-
philic interaction chromatography (HILIC) combined with
positive mode ESI was performed in both analyses. An Acquity
UPLC BEH Amide column (100 mm × 2.1 mm, 1.7 μm;
Waters Corporation, Milford, MA, USA) was used with a flow
rate 0.6 mL/min in analysis 1 and 0.3 mL/min in analysis 2.
The eluents A and B were 50% and 90% ACN, respectively,
both containing 20 mM of pH 3 ammonium formate. In
analysis 1, the gradient was as follows: (0−2.5 min) 100% B;
(2.5−10 min) 100% B → 0% B; (10−10.01 min) 0% B →
100% B; (10.01−12.5 min) 100% B. In the data acquisition,
the mass range was 20−1600 atomic mass unit (amu) with a
scan speed of 600 ms. In the automatic MS/MS analyses,
quadrupole isolation width was 1.3 amu. The amino acids were
verified based on their fragmentation and retention times
relevant to the standard compounds. In the high-resolution MS
quantitation, the following ions were selected: 166.0871 for L-
Phe and 146.9801 for L-Gln. Data acquisition was conducted
with MassHunter Acquisition B.04.00 (Agilent Technologies,
Santa Clara, CA, USA) and processed with Quantitative
Analysis (B.07.00). In analysis 2, the gradient was as follows:
(0−2.5 min) 95% B; (2.5−7.5 min) 95% B → 50% B; (7.5−8
min) 50% B → 95% B; (8−12 min) 95% B. Mass
spectrometric detection was performed with MRM in the
positive mode with the following transitions: 182 → 164.9 for
L-Tyr; 156 → 110 for L-His; 132.1 → 86.1 for L-Leu. Data was
acquired using the software Agilent MassHunter Workstation
Acquisition (Agilent Technologies, Data Acquisition for Triple
Quad., B.03.01) and processed with Quantitative Analysis
(B.04.00) software. The methods were determined to possess
acceptable (≤15% of the relative standard deviation) precision
and accuracy. The calibration curve showed good linearity
(determination coefficients R2 > 0.980). The LLOQ for of L-
Phe, L-Gln, L-Tyr, L-His, and L-Leu ranged between 0.05 and
0.1 nM, respectively.
Data Analysis. The data are presented as median (range)
for protein expression levels and as mean ± SD for Vu,brain,
Abrain, and f u,brain/plasma. Data analysis was done using GraphPad
Prism, version 5.03 (GraphPad Software, San Diego, CA).
■ RESULTS
Evaluation of Intrabrain Distribution Using the Brain
Slice Method. The results from the intrabrain distribution
Table 1. NeuroPK Parameters Characterizing Intrabrain Distribution in Mice and Ratsa
unit ketoprofen prodrug prodrug after LAT1 inhibitor LAT1 inhibitor
Mice
f u,brain 0.15 ± 0.018
b 0.067 ± 0.012b 0.067 ± 0.011c 0.01b
Vu,brain mL/g brain 1.47 ± 0.403 24.3 ± 6.07 16.9 ± 1.11 4.71 ± 0.848
Kp,uu,cell 0.197 1.46 1.01 0.0450
Abrain nmol/g brain 241 ± 10.3 2800 ± 207 1450 ± 43.8 3180 ± 227
Rat
f u,brain 0.24
b 0.030 ± 0.004 0.030 ± 0.004c 0.015 ± 0.001
Vu,brain mL/g brain 1.84 ± 0.162 31.4 ± 2.73 22.2 ± 3.44 5.14 ± 0.446
Kp,uu,cell 0.240 1.87 1.32 0.0490
Abrain nmol/g brain 247 ± 5.60 3050 ± 144 1850 ± 37.8 3280 ± 66.6
aFraction of unbound drug ( f u,brain), unbound volume of distribution in brain (Vu,brain), unbound intra-to-extracellular concentration ratio
(Kp,uu,cell), and the amount of the compound in the brain slice (Abrain) for ketoprofen or prodrug (200 nM) with or without 30 min pre-incubation
with the LAT1 inhibitor (800 nM) in mouse and rat brain slices. Data are presented as mean ± SD. bValue was measured and reported
previously.15,22,28 cWe suggested that the LAT1 inhibitor would not affect brain tissue binding properties of prodrug. Hence, f u,brain of the prodrug
with and without the LAT1 inhibitor was assumed to be the same.
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study demonstrated that the prodrug had more than 16 times
higher value of Vu,brain than ketoprofen itself in both mice and
rats (Table 1). Both compounds reached equilibrium between
aECF and brain slices within 5 h (Figure S2). The incubation
of brain slices with the selective LAT1 inhibitor decreased
Vu,brain of the prodrug by approximately 30% in both mice and
rats.
No released ketoprofen from the prodrug was detected in
either brain slices or aECF during the experiments. The f u,brain
of ketoprofen (0.15 and 0.24) was higher than that of the
prodrug (0.067 and 0.030) in both mice and rats, respectively.
The Kp,uu,cell displayed a higher intracellular distribution of the
prodrug (≥1) in comparison to the parent drug (<1) in both
species. Moreover, there was a subtle species difference in
Kp,uu,cell and Vu,brain of both ketoprofen and prodrug with higher
levels observed in rats, whereas the amounts of ketoprofen and
prodrug in brain slices were similar in both species (Table 1).
The Kp,uu,cell of the prodrug decreased after incubation with the
LAT1 inhibitor. The inhibitor itself reached equilibrium within
5 h (Figure S2) and demonstrated around 5-fold lower Vu,brain
than the prodrug in both species.
Transporter Expression in Brain Slices. The study
demonstrated that a 5 h incubation with or without prodrug or
the LAT1 inhibitor did not alter the crude membrane protein
expression of LAT1, but CD98 normalized to the expression
levels of Na+/K+ ATPase in mouse and rat slices (Figure 2).
There was a trend toward a decrease in normalized LAT1
protein expression levels in rat slices after incubation for 5 h,
which was more pronounced in the LAT1 inhibitor
coincubation group. The LAT1 absolute expression levels
were not species-dependent and ranged from 0.37 to 0.82
fmol/μg in mouse slices vs 0.58 to 1.27 fmol/μg in rat slices
(Table S2). CD98 had lower expression than LAT1 with
absolute levels of 0.19−0.58 fmol/μg in mice and 0.28−1.13
fmol/μg in rats. GLUT1 protein expression levels remained the
same during the experiments, evidence that there had been no
disturbance in energy metabolism in brain slices. GLUT1
expression in brain crude membrane was more than 3 and 10
times higher than that of LAT1 and CD98, respectively
(Figure 2).
Effects of Prodrug and LAT1 Inhibitor on Amino Acid
Transport. The potential of the prodrug and LAT1 inhibitor
to interfere with the transport of the main endogenous amino
acids, substrates of LAT1, such as nonessential glutamine (L-
Gln) and essential amino acids (L-Phe, L-Leu, L-His, L-Tyr),
was evaluated in mouse and rat brain slices (Figure 3). It was
observed that concentrations of L-His, L-Tyr, and L-Phe in
mouse and rat brain slices remained the same during the 5 h
incubation with or without the prodrug or the LAT1 inhibitor.
However, the incubation with or without the prodrug or the
LAT1 inhibitor reduced the concentrations of L-Gln from 8.7−
11.6 nmol/g brain to 3.2−4.7 nmol/g brain in mouse slices
and from 6.5−8.6 nmol/g brain to 1.7−2.5 nmol/g brain in rat
slices. Similarly, L-Leu concentrations in mouse and rat slices
were reduced from 10.3−12.9 nmol/g brain to 6.1−9.4 nmol/g
brain and from 21.8−30.4 nmol/g brain to 8.5−13.3 nmol/g
Figure 2. LAT1, CD98, and GLUT1 protein expression levels in crude membranes of mouse (A) and rat (B) brain slices at baseline (●, Ctrl 0 h),
after 5 h of incubation in aECF (▲, Ctrl 5 h), and after 5 h incubation in aECF containing 200 nM prodrug (○, PD 5 h) or 800 nM LAT1
inhibitor (■, Inh 5 h). The protein expression levels were normalized to that of the membrane marker, Na+/K+-ATPase. The data is presented for
each experiment illustrating values from individual animals (n = 3 per group).
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brain, respectively, after the 5 h incubation with or without the
prodrug or LAT1 inhibitor as compared to control.
There was a change in aECF concentrations of the
investigated amino acids observed after the incubation ranging
from 1 to 5 h in the mouse and rat brain slices with or without
prodrug or LAT1 inhibitor (Figure 3). The aECF concen-
trations of L-His after 5 h incubation of mouse slices as well as
L-Tyr after incubation of either mouse or rat slices decreased
by more than 1.5 (L-His) or 3.5 times (L-Tyr). In contrast, the
incubation of rat slices with or without prodrug or LAT1
inhibitor did not affect aECF levels of L-His, these ranged from
0.6−1.9 nM. The aECF concentrations of L-Gln, L-Phe, and L-
Leu approximately doubled from 1 to 5 h incubation with or
without prodrug or LAT1 inhibitor in both species.
Combining NeuroPK Parameters in Mice. The
integration of parameters derived from the present intrabrain
distribution study, equilibrium dialysis, and the previously
reported PK study15 using the CMA26 provided important
Figure 3. Concentrations of LAT1-utilizing amino acids measured in mouse and rat brain slices as well as aECF: L-His (A), L-Tyr (B), L-Gln (C), L-
Phe (D), L-Leu (E). The data is presented for each experiment illustrating the values obtained from the individual animals (n = 3 per group). The
concentrations in brain slices were measured at baseline (●, Ctrl 0 h), after 5 h of incubation in aECF (▲, Ctrl 5 h), and after 5 h incubation in
aECF containing 200 nM prodrug (○, PD 5 h) or 800 nM LAT1 inhibitor (■, Inh 5 h). The concentrations in aECF were measured after 1 and 5
h of incubation (▲) without compounds and with either the prodrug (○) or the LAT1 inhibitor (■).
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.9b00502
Mol. Pharmaceutics 2019, 16, 3261−3274
3268
information about neuroPK of the prodrug of ketoprofen in
mice. Ketoprofen had a more than 8 times lower Kp,brain value
than the prodrug (Table 2). The Kp,brain of ketoprofen was 13
times lower than that of the parent drug released from the
prodrug; this is evidence that the ketoprofen detected in the
brain after prodrug dosing had been mainly bioconverted in
the brain. In contrast, Kp,uu,brain of the prodrug was 7 times
lower than the corresponding value for ketoprofen. Interest-
ingly, approximately 0.5% and 0.8% of plasma unbound
prodrug were distributed to extra- and intracellular compart-
ments, respectively (Figure 4). In contrast, the unbound
ketoprofen accounted around 4% and 0.9% of plasma unbound
levels in brain ECF and ICF, respectively. Importantly, the
parent drug released in the intracellular compartment of the
brain parenchyma accounted for approximately 11% of plasma
released ketoprofen (Figure 4), demonstrating a significantly
greater intracellular distribution between ICF and plasma in
comparison to ketoprofen dosing (only 0.9%).
Table 2. NeuroPK Parameters Assessed after a Single Dose of 25 μmol/kg i.p. Injection of Either Ketoprofen or the Prodrug in
Mice Using the CMAa
prodrug
unit ketoprofen prodrug ketoprofen released from prodrug
Experimentally Measured Parameters
AUCtotal,brain
b nmol·min/g 12.3 4.1 (6.3)
AUCtotal,plasma
b nmol·min/mL 12757 525 521
Kp,brain 0.0009 0.008 0.012
fu,plasma
b 0.014 ± 0.001 0.059 ± 0.003 0.014 ± 0.001c
Parameters Estimated Using the CMA
Kp,uu,brain 0.042 0.006 0.042
c
AUCu,brainECF nmol·min/g 8.2 0.17 0.32 (4.2)
AUCu,brainICF nmol·min/g 1.61 0.25 0.068 (0.83)
AUCu,plasma
b nmol·min/mL 179 31.0 7.3
aData in parentheses is presented for ketoprofen quantified in the brain,15 which includes both ketoprofen released in plasma and passing into the
brain as well as the parent drug, which had been bioconverted in the brain. The total brain concentration of compounds was corrected with respect
to the residual blood concentration. bParameters evaluated in the previous study.15 cWe assumed the parameter to be equal to the value obtained
after ketoprofen dosing.
Figure 4. Integrated picture comparing the BBB transport and brain extra- and intracellular distribution of unbound ketoprofen and the ketoprofen
prodrug as well as the release of ketoprofen. The cyclooxygenase (COX) target is located in the brain intracellular compartment (indicated by the
star). The figure shows the percentage of AUCu,plasma of ketoprofen, prodrug, and parent drug released from prodrug which had been distributed to
different brain compartments. The schematic representation was made using the CMA and integration of parameters obtained from the PK study in
mice after a single dose of 25 μmol/kg i.p. of ketoprofen or prodrug,15 brain slice study in mice, and equilibrium dialysis study, where nmol·min/g
is assumed to be equal to nmol·min/mL.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.9b00502
Mol. Pharmaceutics 2019, 16, 3261−3274
3269
■ DISCUSSION
Intrabrain Distribution of Ketoprofen and Prodrug in
Mice. The study provided novel mechanistic insights into the
neuroPK of the LAT1-utilizing prodrug of ketoprofen focusing
on its intrabrain distribution and the release of the parent drug
within the brain. The LAT1-utilizing prodrug of ketoprofen,
selected from our previous study,15 achieved a higher extent of
intracellular distribution from brain ECF than the parent drug,
ketoprofen. Thus, in contrast to ketoprofen (Vu,brain, 1.5 mL/g
brain), the Vu,brain of the prodrug (24.3 mL/g brain) was much
higher than the volume of brain fluids, i.e., 0.8 mL/g brain.
Kp,uu,cell, which was used to assess the brain cellular barrier
transport, was above unity for the prodrug, evidence that the
compound was distributed intracellularly, whereas the Kp,uu,cell
of ketoprofen was below unity, indicative of a predominantly
extracellular distribution of the drug.
Importantly, after the incubation with the LAT1 inhibitor,
Vu,brain and Kp,uu,cell of the prodrug decreased by 30%, revealing
the involvement of LAT1 in the brain intracellular distribution
of the prodrug. The IC50 of the LAT1 inhibitor previously
measured as the uptake reduction of a known LAT1 substrate
[14C]-L-leucine in human breast cancer (MCF-7) cells was 18
μM,28 which is more than 20 times greater than the
concentration used in the brain slice experiments (0.8 μM
LAT1 inhibitor). Therefore, in the present study, it was not
expected that there would be any remarkable reduction in
Vu,brain of the prodrug. Interestingly, the Kp,uu,cell of the LAT1
inhibitor was 0.045 indicative of a very low intracellular
distribution of the compound. This confirms our previous
findings that the inhibitor binds reversibly to LAT1 without
intracellular accumulation to any meaningful extent.28
Importantly, both subunits of the transporter, LAT1 and
CD98, were quantified in crude membrane fraction of the
brain slices. Their protein expression levels were not altered
during the 5 h incubation with or without the LAT1 inhibitor
(Figure 2). Thus, the reduction in brain intracellular
distribution of the prodrug after incubation with the LAT1
inhibitor was not caused by any alteration in the expression of
the transporter protein.
Released ketoprofen was not detected during the 5 h
incubation with the prodrug, in either mice or rat brain slices.
These results are consistent with the previous findings,
highlighting the absence of bioconversion of this prodrug in
vitro in mouse liver S9 fractions.15 However, according to the
in vivo PK data, the conversion to ketoprofen occurred after
single dose injection of prodrug in plasma, liver, and brain in
mice.15 We speculate that the absence of in vitro bioconversion
is due to the lack of cofactor(s) of the relevant enzymes in the
experimental settings. Additional studies will be needed to
identify the metabolizing enzyme(s) and their tissue-specific
expression.
NeuroPK Parameters Estimated with the CMA. This is
the first time that the brain intracellular distribution of the
LAT1-utilizing prodrug has been estimated and compared to
that of parent drug using the CMA (Figure 4). Although
prodrug had 7 times lower Kp,uu,brain than ketoprofen,
approximately 1% of plasma levels of both compounds were
distributed to the brain parenchymal cells, where the COX
enzyme is located. This can be explained by a higher extent of
brain intracellular distribution of the prodrug from ECF
compared to ketoprofen. The findings are in accordance with
the cerebral microdialysis study in rats conducted by Gynther
et al.,22 where the lysine prodrug of ketoprofen had a lower
value of Kp,uu,brain (0.09) than ketoprofen (0.12), while the
overall plasma to brain intracellular delivery efficiency of the
prodrug was almost 2-fold greater than ketoprofen.
Importantly, we estimated that the delivery from plasma to
the brain intracellular compartment of released ketoprofen was
11 times higher than that after ketoprofen dosing. However, as
the CMA used in the evaluation of AUCu,ICF might
underestimate this parameter, the difference in the ratio of
unbound released ketoprofen in ICF and plasma compared to
the parent drug may be even larger. Interestingly, ketoprofen,
which had been bioconverted from the prodrug in plasma,
contributed only minimally (9%) to the estimated brain
intracellular levels of ketoprofen after prodrug dosing. This is
convincing evidence that the parent drug had been mostly
delivered into the brain parenchyma in the prodrug form.
Previously, we found a five times higher distribution of the
released ketoprofen from prodrug between mouse brain and
liver compared to ketoprofen dosing.15 The combination of
these findings with 11 times higher brain intracellular
distribution of the released ketoprofen as compared to
ketoprofen dosing suggests that with a LAT1-utilizing prodrug
in mice one can achieve a targeted delivery of ketoprofen to
the brain intracellular compartment, where COX is located.
This means that it might be possible to administer a sufficiently
high dose of the prodrug to achieve effective brain intracellular
concentration of the released ketoprofen while not exposing
peripheral tissues to toxic ketoprofen levels. This would
potentially reduce the drug’s systemic adverse effects. In case
of proven efficacy of ketoprofen in neurodegenerative diseases
such as AD, the prodrug strategy can be promising for
improving brain delivery of this drug in patients.
Thus, as exemplified by ketoprofen prodrug in the present
study, the LAT1-utilizing prodrug approach can enable
targeted brain delivery of drugs, in particular into the brain
parenchymal cells with reduced peripheral exposure to the
released parent drug. Although these findings should be
confirmed in a bigger set of prodrugs of various CNS drugs,
the study highlights the importance of the approach
application for the drugs with the brain intracellular rather
than extracellular targets.
Effect of Prodrug on LAT1 Protein Expression and
Function. As transporters play a pivotal physiological role in
the delivery of endogenous compounds, the development of
influx-transporter utilizing prodrugs has to be based on an
understanding of impact of the prodrug on the transporter
function and protein expression. Here, we report for the first
time that the LAT1-utilizing prodrug of ketoprofen had no
effect on the protein expression of light (LAT1) and heavy
chain (CD98) subunit of the transporter in crude membranes
of mouse and rat brain slices after the 5 h incubation (Figure
2). In addition, during the incubation, there was the exchange
of four essential amino acids (L-Phe, L-Leu, L-His, L-Tyr) and a
nonessential L-Gln between brain slices and aECF providing
evidence that LAT1 was functional in both species. Thus, L-His
and L-Tyr concentrations in aECF decreased throughout the
incubation from 1 to 5 h highlighting their participation in the
antiport of other amino acids. When the latter amino acids
reach equilibrium, L-His and L-Tyr accumulated in brain slices
showing the same levels after the 5 h incubation. In contrast, L-
Phe, L-Leu, and L-Gln concentrations in aECF doubled during
the 5 h incubation in mice and rats. The brain slice
concentrations of L-Gln and L-Leu decreased, while the levels
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of L-Phe in brain slices remained the same, demonstrating the
efflux of these amino acids to the aECF. The results of our
study are in accordance with the current knowledge on the
function of the LAT1, i.e., this transporter mediates the inward
flux of His, Leu, Phe, Gln, Tyr, and other amino acids in
antiport with His, Gln, and Tyr with 1:1 stoichiometry (Figure
1).40,41 One important result emerging from this study is that
the distribution of the prodrug into the brain slices did not
alter the exchange of the investigated amino acids in either
species.
Optimal Strategy for the Preclinical Development of
Influx Transporter-Utilizing Prodrugs. Previously, we
proposed a screening strategy for the development of influx-
transporter utilizing prodrugs such as those exploiting LAT1;
this involved the selection of prodrugs based on their
utilization of the transporter for cellular uptake in vitro, BBB
permeation, and preclinical PK.15 In the current study, we
refined the strategy for development of prodrugs and now
propose some additional steps including investigating the
intrabrain distribution as well as determining the impact of
prodrugs on the physiological state of the transporter (Figure
5). Here, we will discuss the interpretation of the important
neuroPK parameters, which should be considered while
developing influx-transporter utilizing prodrugs for the brain
delivery of drugs with intracellular targets.
The single dose PK study is essential for the investigation of
the BBB transport extent of unbound prodrugs utilizing LAT1
and, more importantly, for the evaluation of the release of
parent drug inside the brain. The extent of BBB transport of
the unbound prodrug can be estimated by measuring Kp,brain or
calculating Kp,uu,brain.
42 The latter parameter can be assessed by
direct measurement of the unbound prodrug in plasma and
brain ECF either using cerebral microdialysis techniques or
estimated with the CMA.26 It is important to bear in mind that
Kp,brain is affected by the nonspecific binding of the compound
to different components within the brain tissue and blood,
while Kp,uu,brain characterizes the net passive and active drug
transport and equilibration across the BBB. Thus, the 8-fold
higher Kp,brain of the prodrug as compared to ketoprofen
revealed in this study could be misleading and interpreted as
higher BBB transport of the prodrug. In contrast, a true
measure of the BBB transport, Kp,uu,brain, revealed that the
prodrug had a 7 times lower extent of the BBB transport
compared to ketoprofen. This variation is mainly due to
differences in brain binding and intrabrain distribution.
Although Kp,uu,brain is a parameter widely used for CNS drug
candidate screening, basing the selection of prodrugs merely
on their Kp,uu,brain values can be misleading. One should
remember that despite a low Kp,uu,brain, prodrugs might have
higher extent of brain cellular barrier transport (Kp,uu,cell)
compared to the parent drug, which governs the brain
intracellular distribution of prodrugs followed by their
potential bioconversion in the brain intracellular compartment.
These latter properties are in fact desirable for the develop-
ment of LAT1-utilizing prodrugs. Therefore, in a prodrug
approach, the focus should be placed on assessing both the
Kp,uu,brain value of a prodrug as well as the intrabrain
distribution of the prodrug and the release of parent drug
within the brain. Thus, during the selection of prodrugs, it is
recommended that compounds with values of Kp,uu,cell greater
than unity due to the confirmed transporter related uptake
should be prioritized. This can be determined in vitro by using
a combination of brain slice and brain homogenate studies,
even before embarking on in vivo studies.
Another key issue in the development of the transporter-
utilizing prodrugs is understanding of interspecies differences
in the tissue-specific protein expression of the transporter and
enzyme(s) responsible for the bioconversion of the prodrug.
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For example, differences in the transporter and enzyme
expression may eventually result in interspecies variations in
brain delivery of prodrug and the release of parent drug,
respectively. While limited information about the prodrug
metabolizing enzymes in the brain is available, the LAT1
protein expression has been quantified in plasma membranes
of cortex microvessels isolated from humans (0.43 ± 0.09
fmol/μg protein), mice (2.19 ± 0.21 fmol/μg protein), and
rats (3.00 ± 0.62 fmol/μg protein).9,10 In addition, LAT1
protein expression has been detected in human and mouse
astrocytes, and its mRNA levels were detected in mouse and
rat neurons.10,12,37 In the present study, the protein expression
of LAT1 was the same in crude membrane of mouse and rat
brain slices. The minor difference in intrabrain distribution of
the prodrug with slightly higher Vu,brain in rats (31.4 mL/g
brain, respectively) than in mice (24.3 mL/g brain,
respectively) is in accordance with the values obtained for
the protein expression levels of LAT1 in crude membranes
from these two species. Moreover, the incubation of mouse
and rat brain slices with the LAT1 inhibitor resulted in a
similar reduction of the Vu,brain and Kp,uu,cell. The changes in
amino acid concentrations were similar in all experimental
groups in both species. Overall, these results indicate that the
intrabrain distribution of the LAT1-utilizing prodrug was
similar in mice and rats.
Importantly, in the present study, the estimation of the
concentrations of prodrug and released parent drug in the
brain intra- and extracellular compartments has been done
assuming steady-state. However, as concentration−time
profiles at the target site drive the interaction with the
target(s), the dynamic information about pharmacokinetics of
prodrugs in different body compartments is essential, and it has
to be studied in the future in order to understand and predict
pharmacokinetic−pharmacodynamic relationships.
Finally, the valid application of the proposed approach will
require an assessment of transporter function and expression
not only in physiological but also under pathological
conditions and the subsequent investigation of the pharmaco-
dynamic effect of the prodrugs (which per se are inactive)
compared to parent drug in a relevant (animal) disease model.
In the present study, inhibition of LAT1 was found to modify
the intrabrain distribution of the prodrug by decreasing its
brain intracellular delivery. This suggests that up- or down-
regulation of the transporter expression in pathological
conditions could affect the brain delivery of transporter-
utilizing prodrugs. Recently, Gynther et al. showed that LAT1
function in both mouse BBB and in mouse primary astrocytes
remain unaltered after LPS-induced inflammation or in the
presence of gene mutations in either amyloid precursor protein
(APP) or presenilin (PSEN1) mimicking AD.37 If this holds
true in humans, then one could speculate that the transporter
would be capable of brain delivering therapeutic compounds
including ketoprofen used in the present study, even in
pathological conditions such as AD.
In conclusion, we have determined mechanistic and
quantitative information about the intrabrain distribution of
a LAT1-utilizing prodrug of ketoprofen used as a tool to probe
brain distribution of influx transporter-utilizing prodrugs, by
using a brain slice method in mice and rats. This is the first
time that the brain slice method has been exploited for
investigating the impact of influx transporter on intrabrain
distribution of prodrug. The LAT1-mediated prodrug of
ketoprofen was delivered to the brain intracellular compart-
ment where its target, the COX enzyme, is located.
Importantly, the distribution of the LAT1-utilizing prodrug
did not affect the expression or function of the transporter.
Finally, we propose additional steps to the strategy for the
effective development of prodrugs utilizing influx transporters
exemplified by LAT1 for targeted delivery of drugs into the
brain. These include investigating the intrabrain distribution of
prodrugs and released parent drug, as well as evaluating the
influence of the prodrugs on the transporter protein expression
and function. Overall, this study illustrated that in addition to a
reduction in the peripheral delivery of the parent drug, the
LAT1-utilizing prodrug approach can be a promising way of




The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.molpharma-
ceut.9b00502.
Chemical structures of ketoprofen, prodrug, and LAT1
inhibitor (Figure S1); the uptake dynamics of
ketoprofen, the prodrug, and the LAT1 inhibitor in
aECF during the experiments in brain slices (Figure S2);
probe peptide amino acid sequences and MRM
transitions for the LC−MS/MS analysis of target
proteins (Table S1); absolute protein expression levels
of LAT1, CD98, GLUT1, and Na+/K+-ATPase meas-
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